Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPLETE: Vortioxetine for Emotional Blunting in MDD
NCT03835715Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Oxford Depression Questionnaire at 8 weeks. Started Feb 2019; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03835715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835715.